Barry Singer, ECTRIMS 2021: Flushing and Flushing-related Adverse Events – Results from the Phase 3 EVOLVE-MS-2 Study

It was a pleasure to meet with Dr Barry Singer (The MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, USA) to discuss the results of the phase 3 EVOLVE-MS-2 study, specifically looking at flushing and flushing related-adverse events with diroximel fumarate in patients with relapsing remitting multiple sclerosis. The abstract […]

Bernhard Hemmer, ECTRIMS 2021: Phase 3 Antelope Study Results Investigating Natalizumab Biosimilar PB006 in RMS

touchNEUROLOGY met up with Prof. Bernhard Hemmer (TUM-Klinikum rechts der Isar, Munich, Germany) to discuss the primary data from the phase III Antelope study, investigating proposed natalizumab biosimilar PB006 in relapsing remitting multiple sclerosis. The abstract entitled: ‘Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri® in patients with relapsing remitting multiple sclerosis: primary […]

Le Hanh Hua, ECTRIMS 2021: Siponimod’s Efficacy on Secondary Progressive MS – Post-hoc Analysis of the EXPAND Study

It was a pleasure to meet with Dr Le Hanh Hua (Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA) to discuss the use of siponimod in patients with active secondary progressive multiple sclerosis identifying as Hispanic from the phase 3 EXPAND study. The abstract entitled: ‘Safety and efficacy of siponimod in […]

Michael Hill, ESOC 2021: Nerinetide for the treatment of Acute Ischaemic Stroke – ESCAPE-NA1 Trial Results

We had the pleasure of meeting up with Prof. Michael Hill (University of Calgary, Calgary, Canada) to discuss the use of nerinetide in the treatment of patients who had an acute ischaemic stroke, and the findings from the ESCAPE-NA1 trial. The session entitled “Nerinetide for LVO Neuroprotection: Fact or Fiction?” was presented at the 7th […]

Satralizumab: An Interleukin-6 Receptor-blocking Therapy for Neuromyelitis Optica Spectrum Disorder

touchREVIEWS in Neurology. 2021;17(1):11-5 DOI: https://doi.org/10.17925/USN.2021.17.1.11

Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disease of the central nervous system (CNS) and is known to cause recurrent episodes of optic neuritis and transverse myelitis. Myelitis is radiologically referred to as longitudinal extensive transverse myelitis on spinal cord magnetic resonance imaging (MRI), extending to ≥3 vertebral segments. The disease flare, either at […]

Remote Electrical Neuromodulation for the Acute Treatment of Episodic and Chronic Migraine

touchREVIEWS in Neurology. 2021;17(1):6-10 DOI: https://doi.org/10.17925/USN.2021.17.1.6

Migraine is one of the most prevalent and disabling diseases worldwide, affecting more than one billion people in 2016.1 It is characterized by recurrent headache attacks with nausea/vomiting, photophobia and phonophobia.2 Currently, the first line of acute treatment of migraine is pharmacological; however, pharmacological approaches may be ineffective, poorly tolerated, and need to be limited in use […]

Opicapone: From Preclinical Data to Real-world Evidence

touchREVIEWS in Neurology. 2021;17(1):32-5 DOI: https://doi.org/10.17925/USN.2021.17.1.32

Parkinson’s disease is now considered to be a spreading disease caused by the aggregation of abnormal alpha-synuclein.1 According to Braak et al., in stage I of the disease, alpha-synuclein pathology is found in the olfactory bulb and the dorsal nucleus of the vagus nerve,2 as well as in the enteric nervous system (Auerbach’s and Meissner’s plexuses).3 These observations […]

Cenobamate for the Treatment of Focal Seizures

US Neurology. 2020;16(2):87–97 DOI: https://doi.org/10.17925/USN.2020.16.2.87

Epilepsy is a very common neurological disease, affecting more than 50 million people worldwide and 3.4 million people in the USA.1–3 Focal seizures, formerly partial-onset seizures, are the most common type, making up ≥60% of cases.4–6 Patients with epilepsy have an increased risk of morbidity and mortality, a decreased quality of life and are more likely […]